Patrys Limited · ASX:PAB
Patrys — Investor Presentation (November 2021)
33 slides from Patrys's investor presentation, Nov 1, 2021
Slide 1: Investor Presentation November 2021
For personal use only INVESTOR PRESENTATION November 2021
Slide 2: Safe harbour statement
Safe harbour statement For personal use only The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of los
Slide 3: Overview
Overview For personal use only • Patrys is advancing its novel deoxymab antibody platform to develop a range of new therapeutic candidates that are: • Pan-cancer, independent of specific cell surface proteins • Able to penetrate and kill cancer cells • Able to deliver payloads intracellularly • Able
Slide 4: Investment summary
Investment summary For personal use only Unique antibody Attractive Intellectual platform markets property • Cancer targeting • PARP inhibitors US$2.3B • Global rights • Cross blood brain barrier • DNA repair deals • All cancer indications • Block DNA repair • ADC deals • Humanised antibodies Multip
Slide 5: Company snapshot
Company snapshot For personal use only Shares 1.83B Patrys (ASX: PAB) – 12-month price and volume Market cap A$76M Cash 1 A$9.8M Last qtr burn 1 (A$1.2M) Headquarters Melbourne Board John Read (Chair) James Campbell (CEO & MD) Pamela Klein (NED) Suzy Jones (NED) Michael Stork (NED) Substantial Dr Da
Slide 6: Board of Directors
Board of Directors For personal use only Dr Pamela M. Klein John Read Chairman • Former VP, Development at Genentech, led development • Experienced Chairman and Director in public, of a large portfolio of drugs private and government organisations • Former Chief Medical Officer of Intellikine (acqui
Slide 7: Technology Overview
For personal use only Technology Overview -7-
Slide 8: First anticancer antibody therapeutic targeting DDR
First anticancer antibody therapeutic targeting DDR For personal use only • Deoxymabs are derived from an antibody, 3E10, which was isolated from a mouse model of the autoimmune disease lupus (SLE) • Deoxymabs bind to DNA and have a unique combination of properties: • Cancer seeking: tumors release
Slide 9: Patrys' deoxymab platform
Patrys’ deoxymab platform For personal use only • Patrys’ deoxymab platform is based on humanised versions of the mouse Mouse Humanised 3E10 antibodies • Global rights to 3E10 antibodies for the treatment of cancer were acquired in 2016 • Patrys has created humanised versions of the 3E10 antibodies
Slide 10: Deoxymab platform offers multiple therapeutic approaches
Deoxymab platform offers multiple therapeutic approaches For personal use only Single Agent Combination Therapies Targeted Therapies + • Many cancers have pre-existing defects • Radiation therapy and many chemo drugs • Deoxymabs can direct delivery of in their DNA damage repair (DDR) work by causing
Slide 11: Deoxymab results
For personal use only Deoxymab results - 11 -
Slide 12: PAT-DX1 improves survival in glioblastoma
PAT-DX1 improves survival in glioblastoma For personal use only • Glioblastoma (GBM) is the most common form of primary brain cancer, with approximately 23,000 new cases diagnosed in the US each year Mice with human GBM • GBM is highly aggressive with few effective treatment options (5-year survival
Slide 13: PAT-DX1 improves survival with breast cancer metastases
PAT-DX1 improves survival with breast cancer metastases For personal use only • Approximately 230,000 women are diagnosed with breast cancer in the TNBC 1 Brain Metastases Model US each year • 10%-15% have Triple Negative Breast Cancer (TNBC), an aggressive form with deficiencies in the BRCA1 gene (
Slide 14: PAT-DX1 improves survival in pancreatic cancer
PAT-DX1 improves survival in pancreatic cancer For personal use only • Pancreatic ductal adenocarcinoma (PDAC) is one of the most common and aggressive cancer types, with a 5-year survival rate of 2–9%1 Pancreatic Cancer Model • Globally, 460k new cases and 432k deaths in 2018 100 Control • Limited
Slide 15: PAT-DX3 development path has been initiated
PAT-DX3 development path has been initiated For personal use only • Full sized, IgG deoxymab antibody, PAT-DX3, produced in September 2020 • PAT-DX3 shares biological activity with PAT-DX1, but is differentiated and complementary • Different pharmacokinetic profile • Can cross the blood brain barrie
Slide 16: Many solid tumors have DDR mutations
Many solid tumors have DDR mutations For personal use only Cancer incidence rates (US cases p.a.)1 Brain 25k Breast 284k 60k Pancreatic 150k Colon Ovarian 21k 1 American Cancer Society - Cancer Facts & Figures 2021 estimates Principe et al 2020. Frequency and prognostic value of mutations associated
Slide 17: Combination therapies – improving glioblastoma treatments
Combination therapies – improving glioblastoma treatments For personal use only • Radiation is a mainstay treatment for glioblastoma (GBM) patients Radiation + PAT-DX1 improves survival and is used: • as a monotherapy (less frequently) • post-surgical removal of tumour tissue 71% • in combination wi
Slide 18: PAT-DX3 ADC proof of principle
PAT-DX3 ADC proof of principle For personal use only MCF7 Breast Cancer Model • Antibody drug conjugates are a fast-growing technology • Use antibody to target delivery of toxic payload to cancer cells. Often superior benefits to antibodies alone • Proof of principle study with PAT-DX3 conjugated to
Slide 19: Commercial landscape
For personal use only Commercial landscape - 19 -
Slide 20: Biologics typically transact earlier and at higher valuations than small molecules
Biologics typically transact earlier and at higher valuations than small molecules For personal use only Proportion of total deals1 Number of pre-clinical deals1 Pre-clinical avg. deal size1,2 Majority of biologic deals occur at Significantly more interest in Pre-clinical biologic deals executed the
Slide 21: Recent deals for antibody and DNA Damage Repair drugs
Recent deals for antibody and DNA Damage Repair drugs For personal use only US$6b Recent pre-clinical transactions (licensing, asset and corporate)1 US$4,000m US$4,000m US$3,065m US$2,070m US$1,680m US$1,560m US$1,200m US$1,300m US$1,076m US$890m US$600m Deal date 1Q19 1Q19 3Q19 1Q20 2Q20 2Q20 2Q20
Slide 22: Looking ahead
For personal use only Looking ahead - 22 -
Slide 23: Timeline
Timeline For personal use only CY21 CY22 CY23 4Q 1Q 2Q 3Q 4Q 1Q 2Q Production Engineering GMP production and run formulation PAT-DX1 Pre-clinical GLP toxicology Prepare & file Clinical Phase 1 Aust-HREA (IND) Pre- Cell line Stable cell production Master Cell Bank Additional development line developm
Slide 24: Anticipated newsflow / Milestones to end of 2022
Anticipated newsflow / Milestones to end of 2022 For personal use only PAT-DX1 engineering production run completed Q4 2021 * PAT-DX3 stable cell line development completed Q1 2022 PAT-DX1 GLP toxicology studies completed Q2 2022 * PAT-DX3 final stable cell line selected Q2 2022 PAT-DX1 upstream pro
Slide 25: Risk factors
For personal use only Risk factors - 25 -
Slide 26: Key Risks
Key Risks For personal use only Investment in the Company involves risks that may be higher than the risks associated with an investment in other companies. Securities in the Company carry no guarantee with respect to the payment of dividends, returns of capital or the market value of the securities
Slide 27: Specific Risks - i
Specific Risks - i For personal use only Innovative The Company's product range includes candidates that are in pre-clinical development and need to be technological further tested before they can progress to human clinical trials. Pre-clinical and clinical development of the development Company's p
Slide 28: Specific Risks - ii
Specific Risks - ii For personal use only Reliance on key The responsibility of overseeing the day-to-day operations and the strategic management of the personnel Company depends substantially on its senior management and its key personnel. There can be no assurance given that there will be no detri
Slide 29: Specific Risks - iii
Specific Risks - iii For personal use only Currency risk Revenue and expenditure in overseas jurisdictions are subject to the risk of fluctuations in foreign exchange markets. The Company carries on part of its business outside of Australia and intends to continue to do so. Accordingly, revenues and
Slide 30: General Risks - i
General Risks - i For personal use only Market Conditions The stock market, and in particular, the market for biotech companies, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of such companies. These factors may
Slide 31: General Risks - ii
General Risks - ii For personal use only Liquidity There can be no guarantee that an active market in the Securities will develop or that the price of the Securities will increase. There may be relatively few buyers or a relatively high number of sellers of Securities on ASX at any given time. This
Slide 32: General Risks - iii
General Risks - iii For personal use only Taxation Risks Changes in tax law, or changes in the way tax laws are interpreted ,may impact the tax liabilities of the Company, Shareholder returns, or the tax treatment of a Shareholder’s investment. In particular, both the level and basis of taxation may
Slide 33: Contact
For personal use only CONTACT CONTACT Dr. James Campbell CEO and Managing Director +61 3 9670 3273 info@patrys.com www.patrys.com Patrys Limited (ASX:PAB)